Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo

Imagem de Miniatura
Arquivos
art_PALMA_Development_of_potent_class_II_transactivator_gene_delivery_2017.PDF (1.94 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
DUANGKHAE, P.
DOURADINHA, B.
VIANA, I. F. T.
DHALIA, R.
MAILLIARD, R. B.
BARRATT-BOYES, S. M.
NASCIMENTO, E. J. M.
Citação
GENE THERAPY, v.24, n.6, p.342-352, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Class II transactivator (CIITA) induces transcription of major histocompatibility complex (MHC) II genes and can potentially be used to improve genetic immunotherapies by converting non-immune cells into cells capable of presenting antigens to CD4(+) T cells. However, CIITA expression is tightly controlled and it remains unclear whether distinct non-immune cells differ in this transactivator regulation. Here we describe the development of gene delivery systems capable of promoting the efficient CIITA expression in non-immune cell lines and in primary human cells of an ex vivo skin explant model. Different human cell types undergoing CIITA overexpression presented high-level de novo expression of MHC II, validating the delivery systems as suitable tools for the CIITA evaluation as a molecular adjuvant for gene therapies.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21433
Referências
  1. Asirvatham AJ, 2008, MOL IMMUNOL, V45, P1995, DOI 10.1016/j.molimm.2007.10.035
  2. Barbaro AD, 2005, EUR J IMMUNOL, V35, P603, DOI 10.1002/eji.200425378
  3. Barbaro AD, 2002, EUR J IMMUNOL, V32, P1309, DOI 10.1002/1521-4141(200205)32:5<1309::AID-IMMU1309>3.0.CO;2-4
  4. Barbieri G, 2002, INT IMMUNOL, V14, P839, DOI 10.1093/intimm/dxf060
  5. Beaulieu YB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148753
  6. Belperron AA, 1999, INFECT IMMUN, V67, P5163
  7. Beyer WR, 2002, J VIROL, V76, P1488, DOI 10.1128/JVI.76.3.1488-1495.2002
  8. Bhat KP, 2010, IMMUNOL CELL BIOL, V88, P807, DOI 10.1038/icb.2010.45
  9. Bhat KP, 2010, J BIOL CHEM, V285, P25893, DOI 10.1074/jbc.M110.127746
  10. Bontron S, 1997, MOL CELL BIOL, V17, P4249
  11. Breckpot K, 2007, HUM GENE THER, V18, P536, DOI 10.1089/hum.2007.006
  12. Camacho-Carvajal MM, 2004, INT IMMUNOL, V16, P65, DOI 10.1093/intimm/dxh010
  13. CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367
  14. Chiu E, 2015, J IMMUNOL, V194, P6102, DOI 10.4049/jimmunol.1402026
  15. Clark KR, 2001, CURR OPIN MOL THER, V3, P375
  16. Cressman DE, 2001, J IMMUNOL, V167, P3626
  17. Croft M, 1997, CRIT REV IMMUNOL, V17, P89
  18. Douradinha B, 2014, VIRUS RES, V179, P231, DOI 10.1016/j.virusres.2013.11.007
  19. Fan W, 2013, ASIAN PAC J CANCER P, V14, P987, DOI 10.7314/APJCP.2013.14.2.987
  20. Feltquate DM, 1997, J IMMUNOL, V158, P2278
  21. Frangione V, 2010, INT J CANCER, V127, P1614, DOI 10.1002/ijc.25183
  22. FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
  23. Gialitakis M, 2010, MOL CELL BIOL, V30, P2046, DOI 10.1128/MCB.00906-09
  24. Gourley TS, 2002, J IMMUNOL, V168, P4414
  25. Green MR, 2006, J IMMUNOL, V177, P3865
  26. Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985
  27. Greer SF, 2004, J IMMUNOL, V173, P376
  28. Gresch O, 2012, METHODS MOL BIOL, V801, P65, DOI 10.1007/978-1-61779-352-3_5
  29. Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000
  30. He Y, 2007, CURR OPIN MOL THER, V9, P439
  31. Hu BL, 2011, IMMUNOL REV, V239, P45, DOI 10.1111/j.1600-065X.2010.00967.x
  32. Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221
  33. Jordan Elizabeth T, 2008, J Biomol Tech, V19, P328
  34. KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295
  35. Kim D, 2008, J IMMUNOL, V180, P7019
  36. Kong XC, 2009, J MOL CELL CARDIOL, V46, P292, DOI 10.1016/j.yjmcc.2008.10.023
  37. KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1
  38. LeibundGut-Landmann S, 2004, EUR J IMMUNOL, V34, P1513, DOI 10.1002/eji.200424964
  39. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  40. Lohsen S, 2014, GENES IMMUN, V15, P543, DOI 10.1038/gene.2014.49
  41. Lu XQ, 2003, CANCER IMMUNOL IMMUN, V52, P592, DOI 10.1007/s00262-003-0404-9
  42. Maciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693
  43. Mah C, 2004, MOL THER, V9, P458, DOI 10.1016/j.ymthe.2004.01.006
  44. MartinezSoria E, 1996, INT IMMUNOL, V8, P543, DOI 10.1093/intimm/8.4.543
  45. McCluskie MJ, 1999, MOL MED, V5, P287
  46. Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712
  47. Morgan JE, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150091
  48. Mortara L, 2006, CLIN CANCER RES, V12, P3435, DOI 10.1158/1078-0432.CCR-06-0165
  49. Mortara L, 2009, INT IMMUNOL, V21, P655, DOI 10.1093/intimm/dxp034
  50. MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851
  51. Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61
  52. Nagarajan UM, 2002, J IMMUNOL, V169, P5078
  53. Nakamura MC, 2014, J BONE MINER RES, V29, P287, DOI 10.1002/jbmr.2161
  54. Oliveira SC, 1999, BRAZ J MED BIOL RES, V32, P207
  55. Raval A, 2003, J IMMUNOL, V170, P922
  56. Rice AD, 2014, J VIROL, V88, P7753, DOI 10.1128/JVI.00185-14
  57. Rousseau A, 2016, NATURE, V536, P184, DOI 10.1038/nature18943
  58. Sartoris S, 1998, J IMMUNOL, V161, P814
  59. Scharer CD, 2015, NUCLEIC ACIDS RES, V43, P3128, DOI 10.1093/nar/gkv182
  60. Schlahsa L, 2014, TRANSFUSION, V54, P1961, DOI 10.1111/trf.12631
  61. Schnappauf F, 2003, EUR J IMMUNOL, V33, P2337, DOI 10.1002/eji.200323490
  62. Sisk TJ, 2000, J IMMUNOL, V165, P2511
  63. Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116
  64. Smith MA, 2011, J BIOL CHEM, V286, P7893, DOI 10.1074/jbc.M110.165431
  65. Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000
  66. STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X
  67. Tan PH, 2005, BLOOD, V105, P3824, DOI 10.1182/blood-2004-10-3880
  68. Taxman DJ, 2000, J IMMUNOL, V165, P1410
  69. Thompson JA, 2006, CANCER RES, V66, P1147, DOI 10.1158/0008-5472.CAN-05-2289
  70. Toniolo PA, 2015, J IMMUNOL, V194, P3180, DOI 10.4049/jimmunol.1401635
  71. Ulbricht T, 2012, J CELL BIOL, V199, P49, DOI 10.1083/jcb.201112015
  72. Voong LN, 2008, J BIOL CHEM, V283, P9031, DOI 10.1074/jbc.M706487200
  73. Wang Y, 2005, HUM GENE THER, V16, P187, DOI 10.1089/hum.2005.16.187
  74. Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6
  75. Westerheide SD, 1997, J IMMUNOL, V158, P4812
  76. Wong AW, 2003, NAT IMMUNOL, V4, P891, DOI 10.1038/ni960
  77. Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007
  78. Wu XY, 2011, NUCLEIC ACIDS RES, V39, P9549, DOI 10.1093/nar/gkr651
  79. Xia J, 2015, BBA-GENE REGUL MECH, V1849, P665, DOI 10.1016/j.bbagrm.2015.03.001
  80. Xu Y, 2007, J BIOL CHEM, V282, P26046, DOI 10.1074/jbc.M703652200
  81. Yee CSK, 2005, J IMMUNOL, V174, P1222
  82. Zhong S, 2000, BLOOD, V95, P2748
  83. Zhou XR, 2007, IMMUNOLOGY, V122, P476, DOI 10.1111/j.1365-2567.2007.02674.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03